SK9492000A3 - Pharmaceutical composition containing sibutramine and orlistat - Google Patents

Pharmaceutical composition containing sibutramine and orlistat Download PDF

Info

Publication number: SK9492000A3
Authority: SK; Slovakia
Prior art keywords: formula; compound; orlistat; compounds; treatment
Prior art date: 1997-12-24

Application number

SK949-2000A

Other languages

English (en)

Slovak (sk)

Inventor

David John Heal

Helen Christine Jackson

Original Assignee

Knoll Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-24

Filing date

1998-12-16

Publication date

2001-07-10

1998-12-16 Application filed by Knoll Ag filed Critical Knoll Ag

2001-07-10 Publication of SK9492000A3 publication Critical patent/SK9492000A3/sk

Links

AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims description 33
229960001243 orlistat Drugs 0.000 title claims description 32
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 title claims description 14
229960004425 sibutramine Drugs 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims abstract description 76
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 19
208000008589 Obesity Diseases 0.000 claims abstract description 17
235000020824 obesity Nutrition 0.000 claims abstract description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 15
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 8
KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 17
229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 description 17
239000003826 tablet Substances 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 9
230000004580 weight loss Effects 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000002775 capsule Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
239000003925 fat Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000001030 gas--liquid chromatography Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
PLXKZKLXYHLWHR-OAHLLOKOSA-N (1r)-1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-OAHLLOKOSA-N 0.000 description 1
PLXKZKLXYHLWHR-HNNXBMFYSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@H](CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-HNNXBMFYSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
-1 (2S, 3S, 5S) -5 - [(S) -2-formamido-4-methyl-valeroyloxy] -2-hexyl-3-hydroxy-hexadecanoic acid lactone Chemical class 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000005577 familial hyperlipidemia Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229960003466 sibutramine hydrochloride Drugs 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000008009 topical excipient Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000011680 zucker rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

SK949-2000A 1997-12-24 1998-12-16 Pharmaceutical composition containing sibutramine and orlistat SK9492000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9727131.6A GB9727131D0 (en)	1997-12-24	1997-12-24	Therapeutic agents
PCT/EP1998/008249 WO1999033450A2 (fr)	1997-12-24	1998-12-16	Agents therapeutiques

Publications (1)

Publication Number	Publication Date
SK9492000A3 true SK9492000A3 (en)	2001-07-10

Family

ID=10824083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK949-2000A SK9492000A3 (en)	1997-12-24	1998-12-16	Pharmaceutical composition containing sibutramine and orlistat

Country Status (25)

Country	Link
US (1)	US6403641B2 (fr)
EP (1)	EP1039900B1 (fr)
JP (1)	JP2001527036A (fr)
KR (1)	KR20010033531A (fr)
CN (1)	CN1134257C (fr)
AT (1)	ATE268174T1 (fr)
AU (1)	AU758181B2 (fr)
BG (1)	BG104568A (fr)
BR (1)	BR9814498A (fr)
CA (1)	CA2315259A1 (fr)
CZ (1)	CZ20002392A3 (fr)
DE (1)	DE69824313T2 (fr)
DK (1)	DK1039900T3 (fr)
ES (1)	ES2222001T3 (fr)
GB (1)	GB9727131D0 (fr)
HU (1)	HUP0300615A3 (fr)
IL (1)	IL136733A (fr)
NO (1)	NO20003313L (fr)
NZ (1)	NZ505686A (fr)
PL (1)	PL342099A1 (fr)
PT (1)	PT1039900E (fr)
SK (1)	SK9492000A3 (fr)
TR (1)	TR200001869T2 (fr)
UA (1)	UA70310C2 (fr)
WO (1)	WO1999033450A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6974838B2 (en)	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) *	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6339106B1 (en)	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
GB9914744D0 (en) *	1999-06-24	1999-08-25	Knoll Ag	Therapeutic agents
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
CZ302087B6 (cs)	2000-07-28	2010-10-06	F. Hoffmann-La Roche Ag	Farmaceutický prípravek obsahující orlistat spolu se sekvestrantem žlucových kyselin pro použití pro lécení a prevenci obezity
WO2002083631A1 (fr)	2001-04-13	2002-10-24	Sepracor Inc.	Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US6730319B2 (en)	2001-06-06	2004-05-04	Hoffmann-La Roche Inc.	Pharmaceutical compositions having depressed melting points
WO2004110338A2 (fr) *	2003-06-12	2004-12-23	Biomas Ltd.	Procedes permettant de traiter l'obesite et des troubles lies a l'obesite au moyen de composes contenant du tellure et du selenium
US20050131074A1 (en) *	2003-08-04	2005-06-16	Beckman Kristen M.	Methods for treating metabolic syndrome
DK1744772T3 (da)	2004-05-10	2017-11-20	Univ Copenhagen	Hørfrø til styring af kropsvægt
EP2190303A1 (fr)	2007-09-12	2010-06-02	Københavns Universitet	Compositions et procédés pour mieux supprimer la sensation de faim et réduire la digestibilité d'une énergie non grasse et prolonger l'effet de satiété
US20090214682A1 (en) *	2008-02-22	2009-08-27	Heuer Marvin A	Composition and methods for weight loss in a subject
JP5738011B2 (ja) *	2011-03-04	2015-06-17	株式会社ブリヂストン	二次電池の非水電解液用添加剤、二次電池用非水電解液及び非水電解液二次電池
CN102872062A (zh) *	2011-07-13	2013-01-16	鲁南制药集团股份有限公司	一种治疗或预防肥胖症以及代谢综合症的药物组合物
JP2013147488A (ja) *	2011-12-21	2013-08-01	Taisho Pharmaceutical Co Ltd	固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52768B1 (en)	1981-04-06	1988-02-17	Boots Co Ltd	1-arylcyclobutylalkylamine compounds useful as therapeutic agents
CA1247547A (fr) *	1983-06-22	1988-12-28	Paul Hadvary	Derives de leucine
CA1328881C (fr)	1984-12-21	1994-04-26	Pierre Barbier	Procede pour la fabrication d'oxetanones
GB8531071D0 (en)	1985-12-17	1986-01-29	Boots Co Plc	Therapeutic compound
GB8704777D0 (en)	1987-02-28	1987-04-01	Boots Co Plc	Medical treatment
JP2675573B2 (ja)	1988-03-31	1997-11-12	科研製薬株式会社	脳機能改善剤
IE61928B1 (en)	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
TW381025B (en)	1993-08-05	2000-02-01	Hoffmann La Roche	Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5459164A (en)	1994-02-03	1995-10-17	Boots Pharmaceuticals, Inc.	Medical treatment

1997
- 1997-12-24 GB GBGB9727131.6A patent/GB9727131D0/en not_active Ceased
1998
- 1998-12-16 IL IL13673398A patent/IL136733A/en not_active IP Right Cessation
- 1998-12-16 CA CA002315259A patent/CA2315259A1/fr not_active Abandoned
- 1998-12-16 AU AU22738/99A patent/AU758181B2/en not_active Ceased
- 1998-12-16 PL PL98342099A patent/PL342099A1/xx unknown
- 1998-12-16 KR KR1020007007034A patent/KR20010033531A/ko not_active Ceased
- 1998-12-16 US US09/212,249 patent/US6403641B2/en not_active Expired - Fee Related
- 1998-12-16 DE DE69824313T patent/DE69824313T2/de not_active Expired - Fee Related
- 1998-12-16 TR TR2000/01869T patent/TR200001869T2/xx unknown
- 1998-12-16 JP JP2000526207A patent/JP2001527036A/ja active Pending
- 1998-12-16 WO PCT/EP1998/008249 patent/WO1999033450A2/fr not_active Application Discontinuation
- 1998-12-16 CN CNB988137399A patent/CN1134257C/zh not_active Expired - Fee Related
- 1998-12-16 ES ES98966345T patent/ES2222001T3/es not_active Expired - Lifetime
- 1998-12-16 CZ CZ20002392A patent/CZ20002392A3/cs unknown
- 1998-12-16 SK SK949-2000A patent/SK9492000A3/sk unknown
- 1998-12-16 HU HU0300615A patent/HUP0300615A3/hu unknown
- 1998-12-16 AT AT98966345T patent/ATE268174T1/de not_active IP Right Cessation
- 1998-12-16 BR BR9814498-7A patent/BR9814498A/pt not_active IP Right Cessation
- 1998-12-16 EP EP98966345A patent/EP1039900B1/fr not_active Expired - Lifetime
- 1998-12-16 UA UA2000074417A patent/UA70310C2/uk unknown
- 1998-12-16 PT PT98966345T patent/PT1039900E/pt unknown
- 1998-12-16 NZ NZ505686A patent/NZ505686A/en unknown
- 1998-12-16 DK DK98966345T patent/DK1039900T3/da active
2000
- 2000-06-23 NO NO20003313A patent/NO20003313L/no not_active Application Discontinuation
- 2000-06-28 BG BG104568A patent/BG104568A/bg unknown

Also Published As

Publication number	Publication date
HUP0300615A3 (en)	2005-04-28
NO20003313L (no)	2000-08-11
CA2315259A1 (fr)	1999-07-08
UA70310C2 (uk)	2004-10-15
KR20010033531A (ko)	2001-04-25
HUP0300615A2 (hu)	2003-07-28
AU758181B2 (en)	2003-03-20
ES2222001T3 (es)	2005-01-16
CN1134257C (zh)	2004-01-14
GB9727131D0 (en)	1998-02-25
BR9814498A (pt)	2000-10-10
JP2001527036A (ja)	2001-12-25
WO1999033450A3 (fr)	1999-09-02
PT1039900E (pt)	2004-09-30
US6403641B2 (en)	2002-06-11
ATE268174T1 (de)	2004-06-15
HK1034446A1 (en)	2001-10-26
TR200001869T2 (tr)	2000-10-23
EP1039900A2 (fr)	2000-10-04
CN1284872A (zh)	2001-02-21
EP1039900B1 (fr)	2004-06-02
DK1039900T3 (da)	2004-10-04
NO20003313D0 (no)	2000-06-23
US20020010160A1 (en)	2002-01-24
CZ20002392A3 (cs)	2002-01-16
NZ505686A (en)	2002-07-26
DE69824313D1 (de)	2004-07-08
IL136733A (en)	2004-08-31
DE69824313T2 (de)	2005-08-25
BG104568A (bg)	2001-02-28
WO1999033450A2 (fr)	1999-07-08
PL342099A1 (en)	2001-05-21
IL136733A0 (en)	2001-06-14
AU2273899A (en)	1999-07-19

Publication	Publication Date	Title
US20030130355A1 (en)	2003-07-10	Therapeutic agents
EP1039900B1 (fr)	2004-06-02	Agents therapeutiques contenant sibutramine et orlistat
US6376552B1 (en)	2002-04-23	Treatment of gallstones
US6355685B1 (en)	2002-03-12	Method of treating anxiety disorders
RU2229289C2 (ru)	2004-05-27	Фармацевтическая композиция, содержащая сибутрамин и орлистат
US6441046B1 (en)	2002-08-27	Control of metabolism
SK18822001A3 (sk)	2003-04-01	Terapeutické činidlá
US6232347B1 (en)	2001-05-15	Treatment of osteoarthritis
AU773490B2 (en)	2004-05-27	Treatment of osteoarthritis
US6403650B1 (en)	2002-06-11	Treatment of pulmonary hypertension
US6365632B1 (en)	2002-04-02	Treatment of orthostatic hypotension
US20040198837A1 (en)	2004-10-07	Treatment of neuropathic pain or fibromyalgia
US6288125B1 (en)	2001-09-11	Treatment of hiatial hernia
US20030008897A1 (en)	2003-01-09	Method of controlling weight gain associated with therapeutic drugs
RU2234917C2 (ru)	2004-08-27	Терапевтические средства
US20030013735A1 (en)	2003-01-16	Weight loss after pregnancy
MXPA00006201A (en)	2001-06-26	Pharmaceutical composition containing sibutramine and orlistat
HK1034446B (en)	2004-11-19	Therapeutic agents
WO2000056317A1 (fr)	2000-09-28	Perte de poids apres une grossesse